Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience.

DNR-60 ( P =0.005), adverse versus favorable karyotype ( P =0.03), adverse versus intermediaterisk karyotype ( P =0.005), and NPM1 mutation ( P =0.04) remained significant while DNR-90 versus DNR-60 became borderline significant ( P =0.09); there was no significant difference in the rate of CR/CRi between IDA-12 and DNR-90 ( P =0.64) or between favorable and intermediate risk karyotype ( P =0.23).

also in 10,988 other papers

We did note, however, the near-significant survival advantage for DNR-90 and IDA-12, in the younger age group, even after adjusting for age and karyotype ( Figure 1B ).

also in 2,240 other papers